Oncology – Urological
Guideline | Diagnosis, management, and follow-up of the incidentally discovered adrenal mass
6 Mar, 2023 | 14:16h | UTC
RCT | Temporary cessation vs. continuation of first-line tyrosine kinase inhibitor in advanced clear cell renal cell carcinoma
22 Feb, 2023 | 12:40h | UTCSummary: The STAR trial investigated whether a tyrosine kinase inhibitor drug-free interval strategy was non-inferior to a conventional continuation strategy for first-line treatment of advanced clear cell renal cell carcinoma. All patients received standard dosing schedules of oral sunitinib (50 mg per day) or oral pazopanib (800 mg per day) for 24 weeks before moving into their randomly allocated group. Although non-inferiority could not be concluded for the primary endpoint of overall survival, temporary treatment cessation was found to preserve quality of life and was cost-effective. Therefore, planned breaks in tyrosine kinase inhibitor treatment represent a reasonable option for selected patients with renal cell carcinoma, providing potential lifestyle and health economic benefits. The study provides a rationale for further exploration of treatment breaks in patients with other cancers.
Commentary on Twitter
NOW OF: The STAR open-label ph 2/3 RCT could not conclude that a TKI drug-free interval strategy was non-inferior to a conventional continuation strategy for first-line treatment of advanced clear cell renal cell carcinoma. #rccsmhttps://t.co/xzCU1jdLE7 pic.twitter.com/Ks1Eh0vMId
— The Lancet Oncology (@TheLancetOncol) February 14, 2023
RCT | Rucaparib vs. physician’s choice in metastatic prostate cancer
20 Feb, 2023 | 12:17h | UTCSummary: This phase 3 randomized trial compared Rucaparib vs. physician’s choice control (docetaxel or a second-generation ARPI) in treating metastatic, castration-resistant prostate cancer patients with a BRCA1, BRCA2, or ATM alteration who had disease progression after treatment with a second-generation androgen-receptor pathway inhibitor (ARPI). The study found that the duration of radiographic progression-free survival was significantly longer in the rucaparib group than in the control group. The most frequent adverse events with rucaparib were fatigue and nausea.
Article: Rucaparib or Physician’s Choice in Metastatic Prostate Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Rucaparib Efficacious in Metastatic Castration-Resistant Prostate Cancer – HealthDay
Commentary on Twitter
Original Article: Rucaparib or Physician’s Choice in Metastatic Prostate Cancer (TRITON3) https://t.co/vuHTxqRRyb#GU23 #oncology pic.twitter.com/UrPMOgW4Fo
— NEJM (@NEJM) February 17, 2023
RCT | Adjuvant nivolumab plus ipilimumab not better than placebo for localized renal cell carcinoma after nephrectomy
16 Feb, 2023 | 15:15h | UTCAdjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
RCT | Hyaluronic acid spacer for hypofractionated prostate radiation therapy
13 Feb, 2023 | 12:25h | UTC
Commentary on Twitter
Multicenter randomized clin trial in prostate cancer tested presence or absence of hyaluronic acid rectal spacer before receiving hypofractionated radiation, showed acute grade >2 GI toxicity in 2.9% of pts w/spacer vs. 13.8% in control group #PCSM #RadOnc https://t.co/eTifx0b1x2
— JAMA Oncology (@JAMAOnc) February 9, 2023
Guideline | Management of metastatic castration-naive and castration-sensitive prostate cancer
23 Jan, 2023 | 13:33h | UTC2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer – Canadian Urological Association Journal (PDF here)
See also: Summary of changes (PDF here)
CanRisk-Prostate | A comprehensive, externally validated risk model for the prediction of future prostate cancer
20 Jan, 2023 | 14:22h | UTCCommentary: Risk Model for Predicting the Development of Prostate Cancer – The ASCO Post
News Release: Prostate cancer risk prediction algorithm could help target testing at men at greatest risk – University of Cambridge
Consensus Statement | Management of patients with advanced prostate cancer
18 Jan, 2023 | 14:26h | UTC
RCT | MRI–guided vs. CT–guided stereotactic body radiotherapy for prostate cancer
15 Jan, 2023 | 20:05h | UTC
Commentary from the author on Twitter (thread – click for more)
Pleased to share the primary endpoint results of the randomized phase III MIRAGE trial evaluating whether aggressive margin reduction with MRI-guidance leads to reduced toxicity in the context of prostate SBRT, out today in @JAMAOncology https://t.co/5ZKElUR4uk (1/n)
— Amar Kishan (@AmarUKishan) January 12, 2023
Cohort Study | 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma
11 Jan, 2023 | 14:10h | UTC5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney) – The Lancet Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
🧵1/ Wide adoption of SABR for primary #kidneycancer is limited by long-term data. Online today @TheLancetOncol; 5-yr outcomes in 190 patients. 5% local failure rates, 95% cancer-specific survival. Thanks @ElsevierConnect for 50-day link: #radonc #kcsm https://t.co/kCM8TraJE3
— Shankar Siva (@_ShankarSiva) November 16, 2022
Review | Advances in diagnosis and treatment of testicular cancer.
16 Dec, 2022 | 13:25h | UTCAdvances in diagnosis and treatment of testicular cancer – The BMJ
Podcast | Prostate cancer: screening, advanced testing, and survivorship.
14 Dec, 2022 | 14:48h | UTC#371 Prostate Cancer: Screening, Advanced Testing, and Survivorship – The Curbsiders
RCT | Rogaratinib vs. chemotherapy in patients with advancer urothelial carcinoma selected based on FGFR1/3 mRNA expression.
14 Dec, 2022 | 14:45h | UTC
Commentary on Twitter
👍 FORT-1: Rogaratinib achieves similar response and overall survival as standard chemotherapy in patients with locally advanced or metastatic #UrothelialCarcinoma selected based on FGFR1/3 mRNA expression 👉 https://t.co/5KAIGpCSt6 #JCO #kcsm #blcsm @cnsternberg pic.twitter.com/jDfVzfwr4e
— Journal of Clinical Oncology (@JCO_ASCO) October 31, 2022
RCT | Effects of prostate cancer screening with PSA and MRI followed by targeted biopsy only.
9 Dec, 2022 | 13:32h | UTCProstate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: New prostate cancer diagnostic pathway paves way for general screening – University of Gothenburg
Commentary: MRI-Targeted Biopsy Beneficial for Men With Elevated PSA – HealthDay
Commentary on Twitter
In a prostate-cancer screening trial involving men with lesions shown on MRI, targeted biopsy alone detected half as many clinically insignificant tumors as targeted and systematic biopsy, with few significant tumors missed. https://t.co/1H6pRN4aLR pic.twitter.com/yy3PAtYuZK
— NEJM (@NEJM) December 8, 2022
RCT | Oncological outcome of short-term, intensive chemoresection with mitomycin in nonmuscle invasive bladder cancer.
9 Dec, 2022 | 13:15h | UTCDaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Chemoresection Reduces Need for Surgery in Nonmuscle Invasive Bladder Cancer – Cancer Therapy Advisor
Commentary on Twitter
https://twitter.com/JCO_ASCO/status/1586040163733487617
RCT | Olaparib with or without Cediranib for metastatic castration-resistant prostate cancer.
9 Dec, 2022 | 13:14h | UTCCommentary: Olaparib Plus Cediranib for mCRPC Lowers Radiographic Progression Risk – Renal & Urology News
Commentary on Twitter
Olaparib (#PARPi) combined with cediranib improved median radiographic PFS compared to olaparib alone in metastatic castrate-resistant #ProstateCancer 👉 https://t.co/guuQ0QQwfL #JCO #PCSM @Joseph_W_Kim pic.twitter.com/jr3GHHrndM
— Journal of Clinical Oncology (@JCO_ASCO) November 1, 2022
18F-sodium fluoride PET–CT vs. 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer.
22 Nov, 2022 | 13:09h | UTCIntra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: 18F-NaF PET-CT More Accurate Than 99mTc-MDP SPECT for Detecting Bone Metastasis – Cancer Therapy Advisor
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given radioisotope therapy for prostate cancer.
22 Nov, 2022 | 12:56h | UTCPSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: PSMA-PET SUVmean Linked With Favorable Response to 177Lu-PSMA-617 in mCRPC – Targeted Oncology
Guideline | Management of castration-resistant prostate cancer.
17 Nov, 2022 | 12:28h | UTC
RCT | Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer.
11 Nov, 2022 | 13:55h | UTC[News release – not published yet] Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer – American Society for Radiation Oncology (ASTRO) Annual Meeting
RCT | Photodynamic vs. white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer.
31 Oct, 2022 | 13:51h | UTC
[News Release] RCT | Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer.
27 Oct, 2022 | 12:32h | UTCNews Release: Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer – ASTRO Annual Meeting
RCT | Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel.
27 Oct, 2022 | 12:23h | UTCContinuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study – The Lancet Oncology (link to abstract – $ for full-text)
RCT | Effect of peritoneal fixation on lymphocele formation in robot-assisted radical prostatectomy with pelvic lymphadenectomy.
24 Oct, 2022 | 14:05h | UTCEffect of Peritoneal Fixation (PerFix) on Lymphocele Formation in Robot-assisted Radical Prostatectomy with Pelvic Lymphadenectomy: Results of a Randomized Prospective Trial – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
https://twitter.com/EUplatinum/status/1581244249412341761
Consensus Recommendations | Radiation therapy in oligometastatic prostate cancer.
19 Oct, 2022 | 14:24h | UTCRelated: AUA/ASTRO Guideline: Clinically localized prostate cancer.